Cover Image

Oral anticoagulant therapy for older patients with atrial fibrillation

Mario Bo, Enrico Brunetti
  • Mario Bo
    Section of Geriatrics and Bone Metabolic Diseases, Department of Medical Sciences, University of Turin, Italy | mario.bo@unito.it
  • Enrico Brunetti
    Section of Geriatrics and Bone Metabolic Diseases, Department of Medical Sciences, University of Turin, Italy

Abstract

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias. Its incidence and prevalence increase with age, representing a significant burden for health services in western countries. The most feared consequence of AF is cardio-embolic stroke, accounting for roughly one third of ischemic strokes in the elderly. Oral anticoagulant therapy is currently recommended for patients with AF and a CHA2DS2-VASc score ≥2 in men and ≥3 in women, but it is widely underused, particularly in the oldest patients who, in reason of their higher risk of stroke, might benefit more from it. Among the main reasons for anticoagulant underuse in older patients, advanced age itself, physician’s perceived high risk of age-related and fall-related bleedings, and difficulties in monitoring vitamin K antagonists-based therapies are the most frequently reported.

Keywords

Oral anticoagulant therapy; atrial fibrillation.

Full Text:

PDF
HTML
Submitted: 2017-09-01 16:17:27
Published: 2017-09-29 10:10:01
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
365

Views:
PDF
278
HTML
4

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2017 Mario Bo, Enrico Brunetti

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185